Nimotop and Rashes - a phase IV clinical study of FDA data

Summary:

Rashes is reported as a side effect among people who take Nimotop (nimodipine), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Midazolam, and have Infection.

The phase IV clinical study analyzes which people have Rashes when taking Nimotop. It is created by eHealthMe based on reports of 521 people who have side effects when taking Nimotop from the FDA, and is updated regularly.

What is Nimotop?

Nimotop has active ingredients of nimodipine. eHealthMe is studying from 522 Nimotop users. Check the latest studies of Nimotop.

What is Rashes?

Rashes (redness) is found to be associated with 3,713 drugs and 6,213 conditions by eHealthMe. Check the latest studies of Rashes.

On Jul, 30, 2026

521 people reported to have side effects when taking Nimotop.
Among them, 21 people (4.03%) have Rashes.

Among these 21 people:

How long have people been on Nimotop when they have Rashes? *

What is the gender of people who have Rashes when taking Nimotop? *

female: 42.11 %
male: 57.89 %

What is the age of people who have Rashes when taking Nimotop? *

What are other drugs people take besides Nimotop? *

What are other side effects people have besides Rashes? *

Erythema Multiforme (a type of hypersensitivity reaction): 9 people, 42.86%
Rash Erythematous (redness of the skin): 6 people, 28.57%
Skin Exfoliation (removal of the oldest dead skin cells): 6 people, 28.57%
Itching: 6 people, 28.57%
Hypersensitivity: 3 people, 14.29%
Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection): 3 people, 14.29%
Localised Oedema (fluid retention in a particular part of the body): 3 people, 14.29%
Dermatitis Bullous (inflammation of the skin characterized by the presence of bullae which are filled with fluid): 2 people, 9.52%
Acute Generalised Exanthematous Pustulosis (acute febrile drug eruption): 2 people, 9.52%
Rash Pustular (redness with pustules): 2 people, 9.52%

What are the existing conditions these people have? *

Infection: 7 people, 33.33%
Vasospasm (sudden constriction of a blood vessel, reducing its diameter and flow rate): 2 people, 9.52%
Therapeutic Embolisation: 2 people, 9.52%
Venous Thrombosis Limb (blood clot that forms in a vein in the limb): 1 person, 4.76%
Urinary Tract Infection: 1 person, 4.76%
Subarachnoid Haemorrhage (blood leaks into the space between two membranes that surround the brain): 1 person, 4.76%
Staphylococcal Infection (an infection with staphylococcus bacteria): 1 person, 4.76%
Migraine (headache): 1 person, 4.76%
Meningitis Bacterial (bacterial inflammation of the protective membranes covering the brain and spinal cord, known collectively as the meninges): 1 person, 4.76%
High Blood Pressure: 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Nimotop and have Rashes?

- Check whether Rashes is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Nimotop:

Nimotop (522 reports)

Rashes treatments and more:

Rashes (702,909 reports)

Browse all side effects of Nimotop:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Rashes:

Rashes (3,713 drugs)

Browse all the conditions that are associated with Rashes:

Rashes (6,213 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on nimodipine (the active ingredients of Nimotop) and Nimotop (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.